Urinary CD163 Predicts Complete Renal Response with Zetomipzomib Treatment in the Open-label MISSION Phase 2 Study in Patients with Lupus Nephritis (EULAR 2023) - Apr 2, 2023 - Abstract #POS1143; Pres time: Jun 2, 2023; 09:30 AM - 10:30 AM; Location: Poster View; "*Complete Renal Response: UPCR ≤0.5, eGFR ≥60 mL/min/1.73m 2 or no worsening of eGFR from baseline of ≥25%, prednisone (or equivalent) ≤10 mg and no use of prohibited medication. Conclusion This post-hoc analysis of zetomipzomib data generated from the MISSION Ph2 study suggests that in patients with proliferative LN, uCD163 levels might predict CRR achieved up to 3 months later and could therefore potentially help to guide optimal therapy. Further evidence is needed from larger randomized LN trials with zetomipzomib to confirm the utility and limits of uCD163 as a predictive biomarker."
Clinical • P2 data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • CD163
|
|
J. T. Merrill 1; R. Leff2; A. Fan3; K. Palaniswamy4; N. Henig5; S. Hua6
|